Group Leader
Miquel Vila Bover
Principal Investigator (PI)
Jordi Bové Badell, Marta Martinez-Vicente, Ariadna Laguna Tuset, Jorge Hernandez Vara, Oriol de Fàbregues-Boixar
Researchers
Marta González Sepúlveda, Thais Cuadros Arasa, Helena Xicoy Cortada
PhD Students
Núria Peñuelas Peñarroya, Joan Compte Barrón, Camille Guillard Sirieix, Alba Nicolau Vera, Marina Lorente Picón, Marta Montpeyó, Eddie Pradas, Maria Camprodon, Daniela Michelle Samaniego Toro, Laura Castillo Ribelles
Lab Technicians
Anabelle Parent, Joana Cladera Sastre, Jordi Riera
23
PUBLICATIONS
159
IMPACT FACTOR
6.91
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Laguna A, Xicoy H, Tolosa E, Serradell M, Vilas D, Gaig C, Fernandez M, Yanes O, Santamaria J, Amigó N, Iranzo A, Vila M.
Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder.
NPJ Parkinson’s disease (2021) 7(1):40
DOI: 10.1038/s41531-021-00184-9
IF: 8.651
Franco-Iborra S, Montpeyó M, Plaza-Zabala A, Sebastian D, Vila M, Martinez-Vicente M.
Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease.
Autophagy (2021) 17(3):672-689
DOI: 10.1080/15548627.2020.1728096
IF: 16.016
García-Pardo J, Novio F, Nador F, Cavaliere I, Suarez-Garcia S, Lope-Piedrafita S, Candiota AP, Romero J, Rodriguez B, Bove J, Vila M, Lorenzo-Rivera J, Ruiz-Molina D.
Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease.
ACS Nano (2021) 15(5):8592-8609
DOI: 10.1021/acsnano.1c00453
IF: 15.881
Biondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, Hutchison M, Yahia-Cherif L, Villain N, Habert MO, Arnulf I, Leu-Semenescu S, Dodet P, Vila M, Corvol JC, Vidailhet M, Lehéricy S.
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease.
Brain (2021) 144(10):3114-3125
DOI: 10.1093/brain/awab191
IF: 13.501
Rabaneda-Lombarte N, Serratosa J, Bové J, Vila M, Saura J, Solà C.
The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease.
Journal of Neuroinflammation (2021) 18(1):88
DOI: 10.1186/s12974-021-02132-z
IF: 8.322
Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson’s disease
Principal Investigator: Miquel Vila
Agency: Aligning Science Across Parkinson’s (ASAP)
Funding: 10,975,371.00 USD (Vila group: 1,485,066.00 USD)
Period: 2021-2024
Molecular mechanisms of neuromelanin-linked neurodegeneration in Parkinson’s disease and brain aging
Principal Investigator: Miquel Vila
Agency: Spanish Ministry of Science and Innovation (MICINN)
Funding: 332,750.00 €
Period: 2021-2024
Targeting neuromelanin-linked neuronal dysfunction and degeneration in ageing and Parkinson’s disease using a combined imaging and brain stimulation approach
Principal Investigator: Miquel Vila
Agency: EU Joint Programme Neurodegenerative Disease Research (JPND)
Funding: 729,980.00 € (Vila group: 249,986.00€)
Period: 2021-2023
Sex-based modulation of neuromelanin-linked Parkinson’s disease pathology
Principal Investigator: Miquel Vila
Agency: Michael J. Fox Foundation (USA)
Funding: 199,974.54 USD
Period: 2021-2022
The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies
Principal Investigator: Marta Martinez-Vicente & Jorge Hernandez-Vara
Agency: Instituto de Salud Carlos III
Funding: 245,932.5 €
Period: 2021-2023
Neurosciences
- Research group on Status Epilepticus and Acute Seizures
- Neuroradiology
- Stroke Research
- Gene Therapy at Nervous System
- Clinical and Translational Bioinformatics
- Peripheral Nervous System
- Headache and Neurological Pain
- Cell signaling and Apoptosis
- Neurodegenerative Diseases
- Neurotraumatology and Neurosurgery Research Unit (UNINN)
- Clinical Neuroimmunology
- Pediatric Neurology
- Psychiatry, Mental Health and Addictions
- Neuromuscular and Mitochondrial Pathology